Get the Stockscreener App
0.655
9.75%
0.0582
Pre-market:
.66
0.005
+0.76%
Plus Therapeutics Inc stock is traded at $0.655, with a volume of 8.90M.
It is up +9.75% in the last 24 hours and up +28.61% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$0.5968
Open:
$0.5998
24h Volume:
8.90M
Relative Volume:
0.49
Market Cap:
$90.02M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.2589
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
+9.48%
1M Performance:
+28.61%
6M Performance:
+85.71%
1Y Performance:
-50.75%
1-Day Range:
$0.5998
$0.66
1-Week Range:
$0.55
$0.66
52-Week Range:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.655 | 82.02M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Why global investors buy Plus Therapeutics Inc. (XMP0) stock2025 Price Targets & Free Verified High Yield Trade Plans - Newser
Hines Adds 3 Life-Science Tenants at Levit Green - Realty News Report
Hines' Levit Green signs 3 biotech tenants for 30K-SF of lab and office space - The Business Journals
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting - The Manila Times
Will Plus Therapeutics Inc. (XMP0) stock rise with strong economyTrade Ideas & Precise Buy Zone Tips - Newser
How Plus Therapeutics Inc. stock reacts to Fed rate cutsIPO Watch & Technical Entry and Exit Tips - Newser
Will Plus Therapeutics Inc. (XMP0) stock beat Nasdaq index returns2025 Analyst Calls & Smart Allocation Stock Reports - Newser
Plus Therapeutics' (PSTV) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Aug Highlights: How Plus Therapeutics Inc. stock performs in weak economyMarket Sentiment Summary & Smart Allocation Stock Reports - BỘ NỘI VỤ
Will Plus Therapeutics Inc. stock gain from lower inflationTrade Signal Summary & High Accuracy Trade Alerts - Newser
How higher bond yields impact Plus Therapeutics Inc. (XMP0) stock2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - Newser
How dovish Fed policy supports Plus Therapeutics Inc. (XMP0) stock2025 Price Action Summary & Risk Controlled Daily Trade Plans - Newser
Why Plus Therapeutics Inc. stock is favored by top institutions - Newser
D. Boral Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
Plus Therapeutics (PSTV) Analyst Rating Update: Maintain Buy Rat - GuruFocus
Plus Therapeutics to present breast cancer treatment data at SABCS By Investing.com - Investing.com Nigeria
Plus Therapeutics to present breast cancer treatment data at SABCS - Investing.com
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium - The Manila Times
Plus Therapeutics, Inc. Announces Abstract Acceptance for Spotlight Presentation at San Antonio Breast Cancer Symposium 2025 on Rhenium (186Re) obisbemeda for Leptomeningeal Metastases Treatment - Quiver Quantitative
Plus Therapeutics (NASDAQ: PSTV) lands SABCS 2025 spotlight for LM Phase 1 trial - Stock Titan
How Plus Therapeutics Inc. stock reacts to job market dataFed Meeting & Long Hold Capital Preservation Tips - moha.gov.vn
Plus Therapeutics Eyes Expansion Despite Wider Quarterly Loss - Finimize
H.C. Wainwright reaffirms Buy rating on Plus Therapeutics stock at $2.00 - Investing.com Nigeria
H.C. Wainwright reaffirms Buy rating on Plus Therapeutics stock at $2.00 By Investing.com - Investing.com India
PSTV Stock on November 25, 2025: FDA Meeting, Nasdaq Extension and Humana Deal Put Plus Therapeutics Back in Focus - ts2.tech
Plus Therapeutics completes FDA meeting on REYOBIQ cancer treatment - Investing.com India
Plus Therapeutics completes FDA meeting on REYOBIQ cancer treatment By Investing.com - Investing.com Nigeria
Plus Therapeutics (PSTV) Advances Reyobiq Development After FDA Meeting - GuruFocus
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases - The Manila Times
Plus Therapeutics Announces Completion of U.S. FDA Meeting - GlobeNewswire
Plus Therapeutics Stock (PSTV) Opinions on Humana Coverage Agreement - Quiver Quantitative
Ascendiant Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
Plus Therapeutics (PSTV) Maintains Buy Rating, Lowers Price Targ - GuruFocus
Will Plus Therapeutics Inc. (XMP0) stock outperform global peersWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
Can Plus Therapeutics Inc. stock withstand economic slowdownJuly 2025 Analyst Calls & Daily Technical Forecast Reports - newser.com
Plus Therapeutics, Inc. (PSTV) Stock: Hits Highs as CNSide Gains National Coverage - parameter.io
Plus Therapeutics shares climb after subsidiary secures nationwide Humana coverage - MSN
PSTV: D. Boral Capital Maintains Buy Rating and $5.00 Price Target | PSTV Stock News - GuruFocus
Plus Therapeutics stock rises after subsidiary signs Humana agreement By Investing.com - Investing.com Nigeria
Plus Therapeutics stock rises after subsidiary signs Humana agreement - Investing.com
Plus Therapeutics secures national coverage agreement with Humana for CNSide® cerebrospinal fluid assay for metastatic CNS cancer - MarketScreener
Is Plus Therapeutics Inc. stock ready for breakoutWeekly Risk Report & AI Powered Buy and Sell Recommendations - newser.com
Will Plus Therapeutics Inc. (XMP0) stock issue positive guidancePortfolio Gains Summary & Fast Exit Strategy with Risk Control - newser.com
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - The Manila Times
Plus Therapeutics (NASDAQ: PSTV) Humana agreement lifts CNSide assay coverage to 67M - Stock Titan
How Plus Therapeutics Inc. (XMP0) stock moves on employment dataQuarterly Market Review & Low Volatility Stock Recommendations - newser.com
Is Plus Therapeutics Inc. (XMP0) stock a buy on weaknessJuly 2025 Pullbacks & Proven Capital Preservation Tips - newser.com
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):